Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast inhibits the actions of LTD4 at the... Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
- Mechanism
- Curator reviewed
Binds to the cysteinyl leukotriene receptor. The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene receptors (CysLT) found in the human airway. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.
- Primary indication
- For Protection against second- phase inflamation in exercise-induced bronchoconstriction and Asthma.Curator reviewed
- Formula / weight
- C23H28N2O3S · 412.545 g/mol (avg)
- Code names
- RO 24-5913
Resolves to
BZMKNPGKXJAIDV-VAWYXSNFSA-NSMILESCCC(CC)(CC(=O)NC1=CC(\C=C\C2=NC(=CS2)C2CCC2)=CC=C1)C(O)=OWhat you can answer from here — as of September 20, 2026
Which drugs share a target with Cinalukast, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account